Mutation Clearance after Transplantation for Myelodysplastic Syndrome.

ABSTRACT:

Background

Allogeneic hematopoietic stem-cell transplantation is the only curative treatment for patients with myelodysplastic syndrome (MDS). The molecular predictors of disease progression after transplantation are unclear.

Methods

We sequenced bone marrow and skin samples from 90 adults with MDS who underwent allogeneic hematopoietic stem-cell transplantation after a myeloablative or reduced-intensity conditioning regimen. We detected mutations before transplantation using enhanced exome sequencing, and we evaluated mutation clearance by using error-corrected sequencing to genotype mutations in bone marrow samples obtained 30 days after transplantation. In this exploratory study, we evaluated the association of a mutation detected after transplantation with disease progre

SUBMITTER: Duncavage EJ 

PROVIDER: S-EPMC6309244 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature